Diabetes
- The role of SGLT-2 inhibitors in managing type 2 diabetes
These drugs improve glycemic control and offer cardiovascular and metabolic benefits.
- SGLT-2 inhibitors: A new era in managing diabetic kidney disease starts now
Randomized controlled trials of these new agents had positive outcomes.
- Peripheral artery disease and unusual skin findings
A 68-year-old man was admitted because of worsening skin problems in his legs.
- Diabetes management
Information was omitted from Table 1 on page 596 of the article, Makin V, Lansang MC. Diabetes management: Beyond hemoglobin A1c. Cleve Clin J Med 2019; 86(9):595–600. doi:10.3949/ccjm.86a.18031
- Clinical outcomes in diabetes: It’s not just the glucose (and it’s not so simple)
As we dig deeper into the reduction in cardiovascular deaths seen with some newer drugs, several questions arise.
- Diabetic dyslipidemia with eruptive xanthoma
Off medications for 1 year, her triglyceride level was 10,250 mg/dL, hemoglobin A1c 12.4%.
- Diabetes management: Beyond hemoglobin A1c
Other factors include cardiovascular benefit, weight control, hypoglycemia risk, and cost.